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Abstract
Virotherapy on the basis of oncolytic vaccinia virus (VACV) infection is a promising approach for cancer therapy. In this study
we describe the establishment of a new preclinical model of feline mammary carcinoma (FMC) using a recently established
cancer cell line, DT09/06. In addition, we evaluated a recombinant vaccinia virus strain, GLV-5b451, expressing the anti-
vascular endothelial growth factor (VEGF) single-chain antibody (scAb) GLAF-2 as an oncolytic agent against FMC. Cell
culture data demonstrate that GLV-5b451 virus efficiently infected, replicated in and destroyed DT09/06 cancer cells. In the
selected xenografts of FMC, a single systemic administration of GLV-5b451 led to significant inhibition of tumor growth in
comparison to untreated tumor-bearing mice. Furthermore, tumor-specific virus infection led to overproduction of
functional scAb GLAF-2, which caused drastic reduction of intratumoral VEGF levels and inhibition of angiogenesis. In
summary, here we have shown, for the first time, that the vaccinia virus strains and especially GLV-5b451 have great
potential for effective treatment of FMC in animal model.
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Introduction
Mammary gland tumors are among the most frequently
observed tumors in older female cats [1,2]. In contrast to dogs
and humans, between 85% and 93% of feline mammary tumors
are malignant [1,3]. The prognosis of feline patients with
advanced mammary malignancy is poor, because this disease is
also very often associated with formation of metastases in one or
more organs [1,4–6]. Despite progress in the diagnosis and
treatment of advanced feline cancer, overall patient treatment
outcome has not been substantially improved in the past.
Therefore, there is an urgent need to identify novel agents for
therapy of advanced feline cancer. One of the most promising
novel cancer therapies is oncolytic virotherapy. This method is
based on the capacity of oncolytic viruses to preferentially infect
and lyse cancer cells without causing excessive damage to
surrounding normal tissue. Several oncolytic viruses have been
successfully tested for human therapy in preclinical and clinical
settings (for a review see [7]). However, in contrast to human
studies, only one clinical trial with moderate success for feline
cancer patients has been reported [8].
In the present study, we evaluated for the first time the
therapeutic potential of the new recombinant oncolytic vaccinia
virus GLV-5b451 expressing the anti-VEGF single-chain antibody
(scAb) GLAF-2 against feline mammary carcinoma (FMC). GLV-
5b451 was derived from the oncolytic vaccinia virus LIVP 6.1.1
[9] by inserting the glaf-2 gene [10] encoding the GLAF-2
antibody under the control of the vaccinia virus synthetic early-late
(SEL) promoter [11] into the J2R (encoding thymidine kinase)
locus. VEGF or VEGF-A is a potent key regulator of tumor
angiogenesis and several anti-VEGF strategies have been devel-
oped for the treatment of different cancer patients [12–15]. It was
shown that overexpression of VEGF in malignant tissues does
correlate very well with an unfavorable prognosis for feline cancer
patients with FMC [16,17]. Therefore, new methods or vectors
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allowing more specific targeting and inactivation of VEGF inside
of tumor tissues are urgently needed. We have already shown that
VACV expressing anti-VEGF antibodies exhibited significant
reduction of tumor growth and enhanced inhibition of angiogen-
esis in comparison to control animals [10,11,18,19].
Here, we report that the virus-mediated oncolytic and
immunological effects upon colonization of tumors with GLV-
5b451 followed by constitutive intratumoral production of
functional scAb GLAF-2 led to significant inhibition of tumor
growth and tumor angiogenesis in mice with feline mammary
tumor xenografts.
Materials and Methods
Ethics statement
All mice animal experiments were carried out in accordance
with protocols approved by the Institutional Animal Care and Use
Committee (IACUC) of Explora Biolabs (San Diego, CA, USA;
protocol number: EB11-025) and/or the government of Unter-
franken, Germany, according to the German Animal Welfare Act
(TierSchG)‘‘ (permit number: 55.2-2531.01-17/08 and 55.2-
2531.01-24/12).
The feline cell line DT09/06 was derived from a mammary
carcinoma (Small Animal Clinic, University of Veterinary
Medicine, Hannover, Germany). Preservation of diagnostic
samples taken from animals as part of a medical procedure is a
routine practice and does not require approval by a review board
or consent of the owner. There was no need for study approval by
a named review board institution or ethics committee because the
mammary tumor was removed as part of the medical care of the
patient. Once a tumor is removed from a patient, the tissue
becomes a diagnostic sample. Isolation of a small section of the
tumor does not interfere with diagnostic analysis of the tumor.
Written consent of the owner was obtained for tumor removal and
diagnostic procedures. This consent form is part of the patient’s
medical record.
The F1B cell line was derived from the swollen left subman-
dibular lymph node of a 3-year-old female cat with clinically
diagnosed lymphoma [20].
The canine cell line MTH52c was derived from a malignant
small-cell carcinoma and was already described by Sterenczak et
al. and Gentschev et al. [21,22].
Donor
The cell line DT09/06 was derived from a tumor of a thirteen
year old, female, unspayed British Shorthair cat (Small Animal
Clinic, University of Veterinary Medicine, Hannover, Germany).
Histopathology revealed an ulcerating stage IV mammary
carcinoma with infiltrative growth and planar necrosis, fused with
the abdominal wall. Tumor cell emboli were detected in the
lymphatic vessels while the performed blood count displayed
hyperproteinaemia and leukocytosis. Prognosis was considered
unfavorable due to high risk of relapse and metastasis. The patient
was prepared for palliative operation by combined administration
of antibiotic amoxicillin/clavulanic acid and the non-steroidal
anti-inflammatory drug meloxicam, resulting in a declining
inflammation of the mamma. Subsequently, surgical treatment
was performed, removing part of the inguinal region including the
fascia and the mammary tumor itself. The feline patient was
euthanized three weeks after the operation due to dyspnea.
Cell culture
African green monkey kidney fibroblasts (CV-1) and feline
lymphoma F1B cells (CRL-6168) were obtained from the
American Type Culture Collection (ATCC). DT09/06 cells were
derived from a feline patient with mammary carcinoma (this study)
and the canine cell line MTH52c was derived from a malignant
small-cell carcinoma [21,22].
Cells were cultured in DMEM supplemented with antibiotic-
solution (100 U/ml penicillin G, 100 units/ml streptomycin) and
10% fetal bovine serum (FBS; PAA Laboratories, Pasching,
Austria) for CV-1 and F1B and 20% FBS for MTH52c. DT09/06
cells were cultured in minimum essential medium with Earle’s salts
(MEM) supplemented with 2 mM glutamine, 100 U/mL penicil-
lin G, 100 mg/mL streptomycin, 1 mM sodium pyruvate, 0.1 mM
nonessential amino acids (MEM-C), and 10% FBS. All cell lines
were cultured at 37uC and 5% CO2 in a humidified incubator.
ELISA
For the quantitative determination of feline VEGF concentra-
tions in DT09/06 cell culture supernatants, 56106 cells were
cultured in MEM containing 10% FBS. Cell culture supernatants
were collected at 24, 48 and 72 h and stored at 220uC.
Lysates of virus-treated and untreated DT09/06 primary
tumors were utilized for determination of VEGF presence in the
tumor tissue.
Concentrations of VEGF were determined by VEGF ELISA kit
(Thermo Scientific, Rockford, USA) developed for detection of
human VEGF (cross-reacts approximately 82% to recombinant
feline VEGF; R&D Systems, Inc., catalog number DVE00, page
11,www.RnDSystem.com), in accordance with the manufacturer’s
directions.
For the determination of the affinity and cross-reactivity of
GLAF-2 to VEGF from different species, an ELISA was
performed. For this purpose recombinant feline (5844-CV-010,
R&D Systems, Minneapolis, MN, USA), murine (V4512, Sigma-
Aldrich, St. Louis, MO, USA) and human (V7259, Sigma-Aldrich)
VEGF proteins were pre-coated at a concentration of 100 ng/well
in 96-well ELISA plates and incubated overnight at 4uC. The wells
were washed once with bidest. water and twice with PBS/0.05%
Tween (PBST) and blocked with 100 ml 1% w/v Blocker Casein in
PBS (Pierce, 37528) for 2 h at 37uC. After washing the wells four
times with PBST, wells were incubated with seven two-fold
dilution series of GLAF-2 (2000 to 31.25 ng/ml, GenScript, E.coli
expressed and purified tag-free) for 1 h at room temperature (RT).
PBS was used as a negative control. The wells were washed again
and incubated with a polyclonal rabbit anti-GLAF-2 antibody
(1:1000, GenScript) for 1 h at RT. After washing the wells were
incubated with a HRP-conjugated polyclonal goat anti-rabbit IgG
(H+L) (170-6515, Biorad, 1:5000) for 1 h at RT. The plate was
washed and staining was developed using TMB (T0440, Sigma-
Aldrich) and stopped with 2 N HCl. The ELISA was read at a
wavelength of 450 nm.
Virus strains
Vaccinia virus strain LIVP 6.1.1 was derived from LIVP (Lister
strain, Institute of Viral Preparations, Moscow, Russia) and is an
oncolytic virus strain designed to locate, enter, colonize and
destroy cancer cells without harming healthy tissues or organs [9].
GLV-5b451 virus was derived from the oncolytic vaccinia virus
LIVP 6.1.1 by inserting the glaf-2 gene [10] encoding the GLAF-2
antibody under the control of the vaccinia virus synthetic early-late
(SEL) promoter [11] into the J2R (encoding thymidine kinase)
locus (this study).
Cell viability assays
DT09/06 or MTH52c cells were seeded in 24-well plates
(Greiner Bio-One, Frickenhausen, Germany). After 24 h in
Vaccinia Virus GLV-5b451 for Feline Cancer Therapy
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culture, DT09/06 or MTH52c cells were infected with either
LIVP 6.1.1 or GLV-5b451 using multiplicities of infection (MOI)
of 0.1 and 1.0. The cells were incubated at 37uC for 1 h, then the
infection medium was removed and subsequently the cells were
incubated in fresh growth medium. The amount of viable cells
after infection was measured using 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) (Sigma, Taufkirchen,
Germany). At 24, 48, 72, or 96 h post infection of cells, the
medium was replaced by 0.5 ml MTT solution at a concentration
of 2.5 mg/ml MTT dissolved in DMEM without phenol red and
incubated for 2 h at 37uC in a 5% CO2 atmosphere. After
removal of the MTT solution, the color reaction was stopped by
adding 1 N HCl diluted in isopropanol. The optical density was
then measured at a wavelength of 570 nm in a Tecan Sunrise
Remote microplate reader (Tecan, Ma¨nnedorf, Switzerland).
Uninfected cells were used as reference and were considered as
100% viable.
Viral replication
For the viral replication assay, DT09/06 cancer cells were
infected with LIVP 6.1.1 or GLV-5b451 at an MOI of 0.1. After
one hour of incubation at 37uC, the infection medium was
removed and replaced by fresh growth medium. After 1, 24, 48, 72
and 96 hours, the cells and supernatants were harvested.
Following three freeze-thaw cycles and three times sonification
(3630 s), serial dilutions of the supernatants and lysates were
titered by standard plaque assay on CV-1 cells. All samples were
measured in triplicate.
Western blot analysis
For detection of virus encoded proteins, DT09/06 cells were
harvested and resuspended in SDS sample buffer at 24, 48, 72, or
96 hours post virus infection (hpvi). DT09/06 tumors were
harvested 28 days post infection (dpi) and shredded in SDS
sample buffer using shredder tubes (Peqlab, Erlangen, Germany).
Samples were separated by 10% SDS-Polyacrylamide gel electro-
phoresis and subsequently transferred onto a nitrocellulose
membrane (Whatman GmbH, Dassel, Germany). After blocking
in 5% skim milk in PBS, the membrane was incubated with rabbit
anti-G6 antibody (affinity-purified polyclonal antibody raised
against a GLAF-2 peptide, GenScript, Piscataway, NJ, USA) for
detection of scAb GLAF-2 or polyclonal rabbit anti-vaccinia virus
antibody (ab35219 Abcam, Cambridge, UK). The primary
antibodies were detected using horseradish peroxidase-conjugated
anti-rabbit (ab6721, Abcam, Cambridge, UK) secondary anti-
body, followed by enhanced chemiluminescence detection.
Vaccinia virus-mediated therapy of DT09/06 xenografts
Tumors were generated by implanting 16107 feline mammary
carcinoma DT09/06 cells subcutaneously into the right hind leg of
6- to 8-week-old female nude mice [Hsd:Athymic Nude-Foxn1nu;
Harlan, Netherlands]. Tumor growth was monitored twice weekly
in two dimensions using a digital caliper. Tumor volume was
calculated as [(length6width2)/2]. On day 28, when tumor
volume reached approximately 400 mm3, groups of mice
(n = 13) were injected intravenously (i.v.) either with 16107 pfu
of GLV-5b451 or LIVP 6.1.1 virus or PBS (control) into the tail
vein. The significance of the results was calculated by two-way
analysis of variance (ANOVA) with Bonferroni post-test. Results
are displayed as means +/2 standard deviation (SD). P values of
,0.05 were considered significant. Mice were monitored for
change in body weight and signs of toxicity.
Histological and PCR genetic analysis of tumors
The spontaneous feline tumor surgically removed from a patient
at the University of Hannover, Germany was used for histopath-
ologic analysis. Portions of the tissues were paraffin-embedded,
sectioned and stained with hematoxylin and eosin (H&E) to
identify the tumor type. The feline mammary tumor was classified
histologically as carcinoma.
Tumor cell lines or xenograft tissue samples were analyzed for
the presence of DT09/06 cells by duplex PCR. For this purpose,
DT09/06 cells or DT09/06 primary tumors were processed by
DNeasy Blood & Tissue Kit (50) (Qiagen, Hilden Germany) to
isolate total DNA and then analyzed by PCR, using DNA
Polymerase (Phusion, Finnzymes, Espoo, Finland) and the primers
for feline 12S rRNA gene (for the identification of DT09/06 cells,
forward: 59-AATTGAATCGGGCCATGAA-39 and reverse: 59-
CGACTTATCTCCTCTTGTGGGTGT-39); for murine 12S
rRNA gene (as control, forward: 59-AAATCCAACTTATATGT-
GAAAATTCATTGT-39 and reverse: 59-TGGGTCTTTAGC-
TATCGTCGATCAT-39) [23]. The PCR reaction was run in a
T-Gradient Thermoblock PCR machine (Biometra, Go¨ttingen,
Germany) under the following cycling conditions: initial heat-
denaturation step at 93uC for 2 min, followed by 35 cycles of
93uC/30 sec, 60uC (cat) or 55uC (mouse)/30 sec, and 72uC/
45 sec. The last extension step at 72uC was maintained for 3 min.
The designed primers generated specific fragments of 108 or
96 bp in length for cat or mouse tissues, respectively.
For histological studies of the xenograft model, tumors were
excised and snap-frozen in liquid N2, followed by fixation in 4%
paraformaldehyde/PBS at pH 7.4 for 16 h at 4uC. After
dehydration in 10% and 30% sucrose (Carl Roth, Karlsruhe,
Germany) specimens were embedded in Tissue-Tek O.C.T.
(Sakura Finetek Europe B.V., Alphen aan den Rijn, Netherlands).
Tissue samples were sectioned (10 mm thickness) with the cryostat
2800 Frigocut (Leica Microsystems GmbH, Wetzlar, Germany).
A part of tissue sectioning was performed as described [24,25].
In this case, VACVs were labeled using polyclonal rabbit anti-
vaccinia virus (anti-VACV) antibody (Abcam, Cambridge, UK),
which was stained using Cy2-conjugated donkey anti-rabbit
secondary antibodies obtained from dianova (Hamburg, Ger-
many). Endothelial blood vessel cells were stained with a
monoclonal rat anti-mouse CD31 antibody (BD Biosciences,
Franklin Lakes, NJ, USA) and a Cy3-conjugated donkey anti-rat
secondary antibody from dianova.
Immune cells were labeled using rat anti-mouse MHCII
antibody detecting a polymorphic determinant present on B cells,
monocytes, macrophages and dendritic cells (eBioscience, San
Diego, CA, USA) and Cy3-conjugated secondary antibody
(donkey) obtained from dianova.
The fluorescence-labeled preparations were examined using a
TCS SP2 AOBS confocal laser microscope (Leica Microsystems
GmbH, Wetzlar, Germany) equipped with the LCS 2.16 software
(102461024 pixel RGB-color images) and an Axiovert 200 M
microscope (Carl Zeiss Microscopy GmbH, Go¨ttingen, Germany)
with Axiovision 4.5 software (138861040 pixel gray scale images).
Digital images were processed with Photoshop 7.0 (Adobe
Systems, Mountain View, CA, USA).
Measurement of blood vessel density in the tumor
tissues
Blood vessel density was measured in digital images (6100
magnification) of CD31-labelled 10-mm-thick tumor cross-sections
using Leica LCS 2.16 software. Eight images per tumor were
analyzed per staining (3 tumors per group, 2 sections of each
tumor and 8 images per section). Tonal correction for all images
Vaccinia Virus GLV-5b451 for Feline Cancer Therapy
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was identical to ensure clear visibility of all detectable blood vessels
and comparability of the results. All blood vessels were counted to
obtain the vessel density per image.
Results
The newly established feline mammary cell line DT09/06
is tumorigenic in female nude mice
In cell culture, the newly isolated feline mammary DT09/06
cells were spindle-shaped with long extensions and did not form
closed monolayers (Figure S1A). The doubling time of these cells
was 22.46 h under these cell culture conditions (Figure S1B). The
tumorigenic potential of DT09/06 was examined in 6- to 8-week-
old female nude mice. For this purpose, four different doses of
56105, 16106, 56106 or 16107 DT09/06 cells were subcutane-
ously implanted into the right hind leg of the animals. Ninety-six
percent of the DT09/06-implanted mice developed a detectable
tumor mass. Eight to nine weeks post implantation about 56% of
mice developed tumors of 2000 to 3000 mm3. The histological
examination of the primary tumors revealed atypical epithelial
cells arranged in neoplastic emboli bundles and streams (Figure
S1C).
Finally, the feline origin of DT09/06 cells or DT09/06 primary
tumors was confirmed through duplex PCR analysis (Figure
S1D). The data demonstrated that the feline DT09/06 cell line
was tumorigenic in female nude mice.
Expression of VEGF protein in DT09/06 cancer cells under
cell culture conditions
VEGF is a potent mediator of both angiogenesis and
vasculogenesis in cats and has been proposed as a prognostic
indicator in invasive feline mammary carcinomas (FMCs) [16]
[26–28]. Therefore, we first analyzed the VEGF expression of the
feline mammary cancer cell line DT09/06 under cell culture
conditions (Figure 1). VEGF concentrations were determined
using a VEGF ELISA kit (Thermo Scientific, Rockford, USA)
developed for detection of human VEGF, in accordance with the
manufacturer’s directions. VEGF levels in the supernatant of
DT09/06 cells were 905.66296.47 pg/106 cells (24 hours),
2171.956149.15 pg/106 cells (48 hours) and 3354.956
798.93 pg/106 cells (72 hours). The data revealed that DT09/06
cells constitutively produced VEGF at all tested time points.
Oncolytic vaccinia virus GLV-5b451 expressing the anti-
vascular endothelial growth factor (VEGF) single-chain
antibody (scAb) GLAF-2 efficiently kills feline mammary
carcinoma DT09/06 cells
Five 6104 DT09/06 cells/well were seeded one day prior to
infection in 24-well plates and were then infected with either
GLV-5b451 or LIVP 6.1.1 (non-GLAF-2 expressing parental virus
strain) at MOIs of 1.0 and 0.1, respectively. Cell viability was
analyzed at 24, 48, 72 and 96 hours post virus infection (hpvi) by
MTT-assays (Figure 2). Ninety-six hours after GLV-5b451
infection at MOIs of 0.1 and 1.0, only 29.07% and 6.62%
DT09/06 cells survived the treatment, respectively. At the same
time point and MOIs, we found 26.15% and 13.17% viable
DT09/06 cells after LIVP 6.1.1 infection.
The data demonstrated that GLV-5b451 and LIVP 6.1.1
efficiently infected and destroyed feline mammary carcinoma
DT09/06 cells under these cell culture conditions. There was no
statistically significant difference in the number of viable cells
between the two virus strains. In addition, similar oncolytic effect
was found after GLV-5b451 infection of the feline lymphoma F1B
cells and canine mammary carcinoma MTH52c cells (Figure S2).
GLV-5b451 efficiently replicates in feline mammary
carcinoma DT09/06 cells
DT09/06 cells were infected with either GLV-5b451 or LIVP
6.1.1 at an MOI of 0.1, in order to test the ability of GLV-5b451
to infect and efficiently replicate in feline mammary carcinoma
cells. Standard plaque assays were performed for all samples to
determine the viral titers at different time points during the course
of infection (Figure 3). The maximum viral titers (total) were
observed at 96 hours post virus infection (hpvi) for both GLV-
5b451 (2.986106 pfu/ml) and LIVP 6.1.1 (3.016106 pfu/ml)
(Figure 3). The replication efficiency of the GLAF-2 expressing
GLV-5b451 strain was similar to that of the parental virus LIVP
Figure 1. VEGF expression in feline mammary cancer DT09/06
cells under cell culture conditions. DT09/06 cells in culture
conditions were washed with PBS and cultured in fresh medium with
2% FCS. Culture supernatants were harvested at 24, 48 and 72 h.
Concentration of VEGF in supernatants was represented as pg/106 cells.
Each value represents the mean (n = 3) +/2 standard deviations (SD).
doi:10.1371/journal.pone.0104337.g001
Figure 2. Viability of the feline mammary carcinoma DT09/06
cells after LIVP 6.1.1 or GLV-5b451 infection at MOIs of 0.1 and
1.0. Viable cells were detected using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT). Mean values (n = 3) and standard
deviations are shown as percentages of respective controls. The data
represent two independent experiments. There were no significant
differences between groups (P.0.05).
doi:10.1371/journal.pone.0104337.g002
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6.1.1 in the feline cancer cell line DT09/06 at all tested time
points.
Analysis of anti-VEGF scAb GLAF-2 biosynthesis in GLV-
5b451-infected DT09/06 cells
DT09/06 cells were infected with GLV-5b451 or LIVP 6.1.1
(control) at an MOI of 1.0 in 24-well plates. At different time
points, cells were harvested and analyzed in Western Blot using
anti-G6 or anti-vaccinia virus (VV) antibodies, respectively
(Figure 4). The data clearly demonstrated that GLV-5b451-
infected DT09/06 cells expressed the GLAF-2 protein (Fig-
ure 4A) of expected size (27 kDa). In addition, the GLAF-2
expression correlated well with the expression of vaccinia virus
specific proteins (Figure 4B). No proteins of similar sizes were
detected in uninfected DT09/06 cells (Figure 4). This is evidence
that the GLAF-2 protein was successfully expressed in infected
feline mammary carcinoma DT09/06 cells.
The GLAF-2 antibody specifically recognizes feline VEGF
Since until now the affinity of GLAF-2 to feline (fe) VEGF has
not been characterized yet, we tested the ability of GLAF-2
antibody to bind recombinant feline VEGF (R&D System) by
ELISA. In these experimental settings we used murine (m) as well
as human (h) VEGF as controls. The data demonstrated that this
antibody was functional and recognized all tested VEGFs with
similar efficiency (Figure 5).
A single systemic administration of GLV-5b451
significantly regresses growth of DT09/06 derived tumors
in nude mice
Thirty-nine female nude mice at an age of 6–8 weeks were
implanted with 16107 DT09/06 cells. Four weeks post implan-
tation, all mice developed tumors with volumes of 300 to
400 mm3. Animals were separated into three groups (n = 13) and
were injected with a single dose of GLV-5b451, LIVP 6.1.1
(16107 pfu in 100 ml PBS) or PBS (100 ml) intravenously (i.v.) into
the lateral tail vein. LIVP 6.1.1, a non-GLAF-2 expressing
Figure 3. Comparison of the replication capacity of the vaccinia
virus strains LIVP 6.1.1 or GLV-5b451 in DT09/06 cells. For the
viral replication assay, DT09/06 cells grown in 24-well plates were
infected with either LIVP 6.1.1 or GLV-5b451 at an MOI of 0.1. Cells and
supernatants were collected for the determination of virus titer at
various time points. Viral titers were determined as pfu per well in
triplicates by standard plaque assay in CV-1 cell monolayers. Averages
plus standard deviation are plotted. The data represent two indepen-
dent experiments.
doi:10.1371/journal.pone.0104337.g003
Figure 5. Interactions of purified GLAF-2 antibody with feline,
murine, and human VEGFs. Affinity and cross reactivity of GLAF-2
was demonstrated by ELISA. Equal concentrations of feline, murine, or
human VEGF (100 ng/well) were coated on ELISA plates. Seven two-fold
dilutions of purified GLAF-2 protein ranging from 2000 ng/ml to
31.3 ng/ml were incubated with feline, murine and human VEGFs. PBS
was used as negative control. For further ELISA experimental conditions
see material and methods. ODs obtained for various conc. of GLAF-2
against feline, murine and human VEGF were plotted. ELISA was
repeated in three independent experiments. Each value represents the
mean (n = 3) +/2 standard deviations (SD).
doi:10.1371/journal.pone.0104337.g005
Figure 4. Expression of virus mediated proteins in DT09/06
cells. Western blot analysis of GLV-5b451-, LIVP 6.1.1-infected (MOI of
1.0) or uninfected DT09/06 cells. Protein fractions from cell lysates were
isolated at different time points and separated by SDS/PAGE. Western
blot analysis was performed as described in material and methods.
GLAF-2: anti-VEGF scAb; VVA: Vaccinia virus specific proteins; M:
PageRuler Prestained Protein Ladder # 26616 (Thermo Scientific, Bonn,
Germany), a mixture of ten blue-, orange-, and green-stained
recombinant proteins (10 to 170 kDa), was used as size standards in
Western blotting.
doi:10.1371/journal.pone.0104337.g004
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Figure 6. Growth of feline mammary carcinoma tumors in virus- and mock-treated mice. (A) Groups of DT09/06 tumor-bearing nude mice
(n = 13) were either treated with a single dose of 16107 pfu GLV-5b451, LIVP 6.1.1. or with PBS (mock control). Tumor size was measured twice a
week. Two-way analysis of variance (ANOVA) with Bonferroni post-test was used for comparison of two corresponding data points between groups
and presented as mean values +/2 SD. (****P,0.0001, **P,0.01). (B) Relative mean weight changes of DT09/06 cell xenografted mice after virus or
PBS treatment. The data are presented as mean values +/2 SD.
doi:10.1371/journal.pone.0104337.g006
Table 1. Biodistribution of GLV-5b451 in virus-treated mice bearing DT09/06 xenografts at 28 days post virus injection (dpvi).
PFU per gram (g) of organ or tumor tissue DT09/06 xenografts treated with 16107 pfu GLV-5b451
Mouse No 288 290 337
Tumor 4.66E+07 1.35E+07 4.39E+07
Lung 1.72E+02 7.6E+02 n.d.
Liver 6.94E+03 7.29E+03 2.62E+02
Spleen 1.75E+02 8.33E+03 4.33E+02
Kidney 1.5E+03 4.71E+02 1.0E+02
Ovaries 1.6E+03 n.d. n.d.
The data were determined by standard plaque assay on CV-1 cells using aliquots of the homogenized organs and were displayed as mean pfu per gram of organ or
tissue. For each organ, two aliquots of 0.1 ml were measured in triplicates.
n. d.: not detected (detection limit ,10 pfu/organ).
doi:10.1371/journal.pone.0104337.t001
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parental virus strain of GLV-5b451 virus, was used as an
additional control. Tumor size was measured twice a week. As
shown in Figure 6A, the virus treatment led to significant
differences in tumor growth between PBS controls and all virus-
treated mice from 21 to 28 days post virus injection (dpvi). Due to
excessive tumor burden, more than 50% of the animals of the PBS
control group developed tumors .3000 mm3, we terminated the
experiment at day 28 post injection. In this experimental setting,
we did not find a significant difference between the two virus
treated groups (GLV-5b451 vs. LIVP 6.1.1 P= 0.99). In addition,
the toxicity of the GLV-5b451 virus was determined by
monitoring the relative weight change of mice over time
(Figure 6B). All virus-treated mice showed stable mean weight
over the course of studies. There were no signs of virus-mediated
toxicity.
Biodistribution of GLV-5b451 virus in DT09/06 tumor-
bearing nude mice
Three tumor-bearing mice injected with 16107 pfu of GLV-
5b451 were analyzed for virus distribution. Viral titers were
determined by standard plaque assays on CV-1 cells using aliquots
of the homogenized tissues and were displayed as mean pfu/g
organ or tumor tissue (n = 3). Table 1 summarizes the GLV-
5b451 virus distribution in DT09/06 xenografted mice at day 28
post virus injection. The highest viral titers of about 107 pfu/g
were identified in primary tumors of virus-treated mice. In
contrast, only very few GLV-5b451 virus particles were detected in
whole healthy organs (Table 1). The data clearly showed that
GLV-5b451 virus displayed an enhanced tumor specific replica-
tion.
GLV-5b451 tumor colonization significantly decreases
levels of functional VEGF and inhibits development of
tumor vasculature
To test the effect of the GLAF-2 antibody expression on tumor
angiogenesis, we first analyzed intra-tumoral GLAF-2 and VEGF
levels of GLV-5b451- in comparison to LIVP 6.1.1- or PBS-
treated DT09/06 tumors. In the presence of GLAF-2 antibodies,
we observed a significant decrease of tumoral VEGF concentra-
tion in all GLV-5b451-treated mice but not in LIVP 6.1.1- or
PBS-injected animals (GLV-5b451 vs. LIVP 6.1.1 *P= 0.0122;
GLV-5b451 vs. PBS ****P,0.0001 and PBS vs. LIVP 6.1.1
P= 0.6788) (Figure 7).
In addition, tumor angiogenesis was assessed by CD31
immunostaining and microvessel density analysis. For this
purpose, CD31-labelled cross sections of tumors from LIVP
6.1.1-, GLV-5b451- and PBS-treated mice were compared by
fluorescence microscopy at day 28 after treatment (Figure 8). The
data revealed that the vascular density of GLV-5b451-infected
tumors was significantly decreased in comparison to that of LIVP
6.1.1- and PBS-injected control tumors (GLV-5b451 vs. LIVP
6.1.1 ***P= 0.00031; GLV-5b451 vs. PBS **P= 0.00271) (Fig-
ure 8B). However, significant reduction of the vascular density
was observed in virus-infected areas only (Figure 8B; infected)
which may serve as evidence that this effect was mediated by the
GLAF-2 protein overproduction following virus colonization of
tumors. Moreover, the vascular density of infected areas of GLV-
5b451 tumors was also significantly lower than that of non-infected
areas (infected GLV-5b451 (Figure 8B) vs. non infected GLV-
5b451 (Figure 8C); *P= 0.0484).
The results demonstrate that the virus colonization in combi-
nation with scAb GLAF-2 production led to a decrease of tumoral
VEGF concentration and local inhibition of the blood vessel
development in the GLV-5b451 virus-infected tumor tissue only.
Effect of virus colonization and tumor vascular density on
the presence of immune cells in virus treated DT09/06
tumors
In the last part of our study, we investigated the effects of the
virus infection and tumor vasculature on peri- and intratumoral
infiltration of host immune cells in tumors of DT09/06-tumor-
bearing mice. Cryosections prepared from DT09/06 tumors
resected 28 days after either LIVP 6.1.1 or GLV-5b451 treatment
were analyzed for the presence of MHC II-positive host immune
cells (B cells, monocytes, macrophages and dendritic cells,
Figure 7. Presence of the scAb GLAF-2 and VEGF in tumors of LIVP 6.1.1- or GLV-5b451- injected DT09/06 xenograft mice. (A)
Western blot analysis of DT09/06 tumor xenografts injected with LIVP 6.1.1 or GLV-5b451 virus (n = 3). The presence of GLAF-2 proteins was
performed as described before. Each sample represents an equivalent of 2 mg tumor mass. (B) Levels of functional VEGF in tumor lysates determined
by ELISA. The graph was plotted using the mean values of each group of three independent measurements. The data are presented as mean values
+/2 SD. An unpaired t-test was performed revealing significant differences (****P,0.0001, **P,0.01).
doi:10.1371/journal.pone.0104337.g007
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Figure 9). Interestingly, there was no significant difference in the
number of MHC II-positive cells in tumor tissues infected with
either LIVP 6.1.1 or GLV-5b451 in the late phase of infection.
In summary, the results suggest that the decreased vascular
density after GLV-5b451 treatment did not change significantly
the intratumoral infiltration of MHCII-positive immune cells in
comparison to the LIVP 6.1.1 treatment.
Discussion
Despite advances in surgery, radiation and chemotherapy, the
available treatment options for mammary carcinoma in cats are
limited and the prognosis for patients with advanced-stage disease
is very poor. Therefore, developing novel therapies, which may
also work synergistically in combination with the conventional
treatment options, is crucial. One of the most promising novel
cancer agents are oncolytic viruses with therapeutic payloads.
Several different oncolytic viruses such as herpes simplex virus,
vaccinia virus, seneca valley virus and reovirus are currently in or
entering Phase III human clinical trials. In addition, in China the
oncolytic adenovirus H101 has been approved for the treatment of
human patients with head and neck cancer since 2005 [29]. In
contrast, only few such viruses including myxoma virus [30] and
poxviruses [8], two distinct members of the family Poxviridae,
have been tested for feline cancer therapy with moderate success
(for a review see [31]).
In the current study, we investigated the oncolytic efficacy of the
recombinant vaccinia virus strain GLV-5b451 expressing the anti-
VEGF single-chain antibody GLAF-2 in a new feline mammary
carcinoma cell line DT09/06 in culture as well as in a novel
xenograft model. The results showed that GLV-5b451 was able to
effectively infect, replicate in and lyse the DT09/06 cells in
culture. In addition, the data revealed that the DT09/06 cell line
was tumorigenic in nude mice. About 96% of all implanted mice
developed tumors at the site of injection. However, none of the
tumor-bearing mice showed any signs of metastasis or of invasive
growth pathologically. We therefore assumed that in this case,
time for metastasis formation exceeded the time limitation owed to
local tumor growth in mice. Interestingly, the feline donor had
evidence of lymphatic metastases. Taken together, this xenograft
model may become an useful tool for preclinical studies for
treatment of FMC.
We were able to demonstrate that treatment with the oncolytic
vaccinia virus GLV-5b451 harbouring the gene for the anti-VEGF
scAb GLAF-2 significantly reduced the growth of feline mammary
carcinoma xenografts predominantly by oncolysis and inhibited
tumor angiogenesis simultaneously. VEGF is an important
regulator of tumor angiogenesis and its pathway has been targeted
with antibodies and small molecules [12,13]. One of the best
characterized strategies is the VEGF blockade using the human-
ized anti-VEGF monoclonal antibody (mAb) bevacizumab
(avastin) [32]. However, despite very promising preclinical results,
bevacizumab has not been shown to provide a benefit in patients
with breast cancer as monotherapy (http://www.fda.gov/
NewsEvents/Newsroom/PressAnnouncements/ucm279485.htm).
Another new strategy is to fight tumor vasculature with
oncolytic viruses. This method has already been successfully used
in several different cancer types (for a recent review see [33]). In
the current study, we utilized the combination of oncolytic
vaccinia virus and single chain antibody targeting VEGF in order
Figure 8. Visualization and determination of vascular density using CD31 immunohistochemistry in virus-treated (LIVP 6.1.1 or
GLV-5b451) and PBS-treated tumors at 28 dpvi. (A) Tumor sections labeled with anti-CD31 antibody (red) and anti-vaccinia virus (VV) antibody
(green). Scale bars: 150 mm. (B, C) The vascular density was measured in CD31-labeled tumor cross-sections (n = 3 mice per group, 16 images per
mouse) and presented as mean values +/2 SD. (***P,0.001, **P,0.01,*P,0.05 Student’s t-test).
doi:10.1371/journal.pone.0104337.g008
Vaccinia Virus GLV-5b451 for Feline Cancer Therapy
PLOS ONE | www.plosone.org 8 August 2014 | Volume 9 | Issue 8 | e104337
to improve the anti-angiogenic and vascular-disrupting properties
of our oncolytic virus. We have recently reported that treatments
with recombinant vaccinia virus strains (VACV) expressing anti-
VEGF antibodies (GLAF-1 or GLAF-2) led to enhanced tumor
growth inhibition and vascular disruption in different xenograft
models [10,11,18]. GLAF-1 and GLAF-2 are identical with the
only difference that GLAF-1 contains a FLAG-tag for purification
purposes [11]. Here, using Western blot analysis and VEGF
ELISA we documented that the presence of the anti-VEGF scAb
led to significant decrease of tumoral VEGF protein concentration
in GLV-5b451 virus-colonized tumors only (Figure 7). The
significant higher VEGF concentrations in LIVP 6.1.1-virus-
infected tumors confirmed the assumption that presence of GLAF-
2 in the tumor tissue alone leads to the reduction of local VEGF
level. This fact is also an evidence for the functionality of the
GLAF-2 antibody in tumor tissue. We selected DT09/06
xenografted mice to study the effects of the GLAF-2 scAb on
tumor angiogenesis since the feline mammary carcinoma DT09/
06 cell line showed a constitutively high VEGF expression under
cell culture conditions (Figure 2).
To be sure that the GLAF-2 antibody is functional in feline
mammary carcinoma xenografts, we tested the effect of GLAF-2
on tumor angiogenesis by CD31 immunohistological staining of
DT09/06 tumor sections. CD31 is used primarily to demonstrate
the presence of endothelial cells in tumor tissue sections and is an
effective tool for analysis of microvessel density. The data revealed
a significant decrease in the number of blood vessels in GLV-
5b451 infected tumors when compared to LIVP 6.1.1- and PBS-
injected control tumors at 28 dpvi (Figure 8). In the case of LIVP
6.1.1, the non GLAF-2-expressing parental virus of GLV-5b451,
no reduction of the vascular density was observed. Interestingly,
the significant reduction in vascular density in GLV-5b451
colonized tumors was observed only in virus-infected areas of
the tumors. The reason for this localized effect could be the
reduced number of microvessels in DT09/06 tumors that might
affect the intratumoral spread of GLAF-2 protein. Very similar
data were obtained with GLAF-1 antibody in canine STSA-1
xenograft model [18].
We have also shown for the first time that GLAF-2 can
specifically bind to feline VEGF (Figure 5). In addition, the cross
reactivity of GLAF-2 with murine VEGF was demonstrated. The
GLAF-2-binding to VEGF from both feline and mouse origin is
advantageous in our feline DT09/06 xenograft model, as blocking
of VEGF from both species could be important to enhance
therapeutic efficacy [29].
In the last part of our study we investigated the effect of virus
colonization and the tumoral vascular density on the peri- and
intratumoral infiltration of MHC II-positive host immune cells.
Interestingly, despite a significant reduction of vascular density in
GLV-5b451-treated tumors, we did not notice a significant
difference in the number of MHC II-positive cells in comparison
to LIVP 6.1.1-injected control tumors (Figure 9). These findings
suggest that the reduced vascular density in GLV-5b451-treated
xenografts is not crucial for intratumoral infiltration of host
immune cells at least in the late phase of infection. The presence of
host immune cells (like e.g. macrophages and dendritic cells)
surrounding virus-infected cancer cells could serve as an evidence
for a possible association between vaccinia virus colonization,
activation of the host innate immune system and xenograft
eradication. Moreover, we and others have recently reported that
these interactions may increase the activation and strength of host
antitumor immune responses [25,34–37].
Thus, the anti-tumor mechanism in DT09/06 xenografts could
be a combination of the direct viral oncolysis of tumor cells and
the virus-dependent infiltration of tumor-associated host immune
cells. The observed significant reduction in vascular density in
GLV-5b451 colonized tumors compared to LIVP 6.1.1. tumors
seems to be not essential for the tumor growth inhibition at last till
28 dpvi, since we did not find a significant difference between the
both virus treated groups (GLV-5b451 vs. LIVP 6.1.1 P= 0.99).
However, the inhibition of angiogenesis could be an important
anti-tumoral mechanism in immunocompetent patients.
In conclusion, oncolytic vaccinia virus strains and especially
GLV-5b451 may be promising candidates for therapy of feline
cancer patients with diagnosed mammary carcinoma.
Supporting Information
Figure S1 Analysis of feline mammary carcinoma cells
or tumor tissue by transmitted light microscopy (A),
doubling time of DT09/06 cells in cell culture (B),
histology (C) or PCR (D). (A) Transmitted light microscopy of
uninfected feline mammary carcinoma DT09/06 cells in MEM-C
culture (6100 magnification). (B) Cell counts used to determine
population doubling time of DT09/06 cells. Cells were seeded in
12-well plates with a seeding concentration of 16104 or 26104
DT09/06 cells per ml in triplicates (n = 3). The cells were
harvested after 24, 48, 72 and 96 hours, respectively, and the
mean cell numbers and standard deviations were determined. The
points were plotted using the 24 to 96 h time points. The
Figure 9. Immunohistochemical staining of either LIVP 6.1.1- or
GLV-5b451-treated DT09/06 xenograft tumors at 28 dpvi.
Representative tumor sections labeled with anti-vaccinia virus (green),
anti-MHCII antibodies (red) and Hoechst 33342 staining (blue). Scale
bars: 200 mm.
doi:10.1371/journal.pone.0104337.g009
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exponential trend lines were drawn and the coefficients of
determination (R2) specified. The population doubling time was
identified using the calculator found on www.doublingtime.com/
compute.php. The identified population doubling times were
21.50 h (seeding density of 16104/well) and 23.43 h (seeding
density of 26104/well). The doubling time was 22.46 h under
these cell culture condition. (C) Histological section of a DT09/06
xenograft, right flank, athymic nude mouse (H&E, 6200-
magnification). (D) Electrophoretic analysis of the 12S rRNA
PCR products on 1.6% agarose gels containing Midori Green
(Nippon Genetics Europe GmbH, Du¨ren, Germany). Identifica-
tion of cat and mouse tissues by Duplex PCR with primers either
for feline 12S rRNA gene (F; forward: 59-AATTGAATCGGGC-
CATGAA-39 and reverse: 59- CGACTTATCTCCTCTT-
GTGGGTGT-39), or for murine 12S rRNA gene (M; forward:
59-AAATCCAACTTATATGTGAAAATTCATTGT-39 and re-
verse: 59- TGGGTCTTTAGCTATCGTCGATCAT-39). The
primers designed generated specific fragments of 108 or 96 bp
in length for cat or mouse tissues, respectively [23]. Lanes: 1: PCR
Marker (BioLabs); 2: DT09/06 tumor/F-primers; 3: DT09/06
tumor/M- primers, 4: DT09/06 cells/F-primers; 5: DT09/06
cells/M-primer. Molecular sizes are indicated.
(TIF)
Figure S2 (A) Viability of feline lymphoma F1B cells
after LIVP 6.1.1 or GLV-5b451 infection. 16104 F1B cells
were seeded in 96-well plates and infected with LIVP 6.1.1 and
GLV-5b451 at MOI of 1.0. The amount of viable cells was
measured using 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tet-
razolium-5-carboxanilide inner salt (XTT) assay (Cell Proliferation
Kit II, Roche Diagnostics, Mannheim, Germany), according to
the manufacturer’s protocol at different time points after infection.
Quantification of cell viability was performed in an ELISA plate
reader (SpectraMax M5, Molecular Devices, Sunnyvale, USA) at
450 nm with a reference wavelength of 700 nm. Viral cytotoxicity
was measured at Day 0, 1, 3, 5, 7 and 9. Mean values (n = 4) and
standard deviations are presented as percentages of the respective
uninfected controls defined as 100% viable. (B) Viability of
canine mammary MTH52c carcinoma cells after LIVP
6.1.1 or GLV-5b451 infection at MOIs of 0.1 and 1.0,
respectively. 46105 MTH52c cells were seeded in 24-well plates
and infected with LIVP 6.1.1 and GLV-5b451 at MOIs of 0.1 and
1, respectively. The fraction of viable cells after 24, 48, 72 and
96 hours was detected using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium-bromide (MTT). Mean values (n = 3) and
standard deviations are presented as percentages of the respective
uninfected controls defined as 100% viable. The data represent
two independent experiments. There were no significant differ-
ences between groups (P.0.05).
(TIF)
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